Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA9 | Q16790 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 3/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | CFTR | P13569 | 1/20 | 0.38 |
| ▸ | STAT3 | P40763 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31662487 | 0.92 | CA12 (0.39) | CA12CA1CA9CYP2D6CYP1A2 | |
| SCHEMBL4035337 | 0.92 | CA12 (0.39) | CA12CA1CA9CYP2D6CYP1A2 | |
| SCHEMBL25907366 | 0.92 | ALDH1A1 (0.41) | CA12CA1CA9CYP2D6CYP1A2 | |
| SCHEMBL244134 | 0.89 | CYP2D6 (0.43) | CA12CA1CA9CYP2D6CYP1A2 | |
| SCHEMBL334939 | 0.86 | ACHE (0.44) | CA12CA1CA9CYP2D6CYP1A2 | |
| SCHEMBL336340 | 0.86 | ALDH1A1 (0.44) | CA12CA1CA9CYP2D6CYP1A2 | |
| SCHEMBL7026133 | 0.85 | ALDH1A1 (0.46) | CA12CA1CA9CYP2D6CYP1A2 | |
| SCHEMBL1866143 | 0.85 | CA12 (0.42) | CA12CA1CA9CYP2D6CYP1A2 | |
| SCHEMBL282892 | 0.85 | CYP2D6 (0.40) | CYP2D6CYP1A2MEN1KMT2ACYP3A4 | |
| SCHEMBL967917 | 0.82 | ALDH1A1 (0.43) | CA12CA1CA9CYP3A4CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 64 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210130365-A1 | 2-AZASPIRO[3.4]OCTANE DERIVATIVES AS M4 AGONISTS | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. | 2021-05-06 | — | — | US | disclosed |
| EP-2870156-B1 | PYRIMIDINONE DERIVATIVES AS ANTIMALARIAL AGENTS | SANOFI SA (FR) | 2020-06-17 | — | — | EP | disclosed |
| EP-2870156-B1 | PYRIMIDINONE DERIVATIVES AS ANTIMALARIAL AGENTS | SANOFI SA (FR) | 2020-06-17 | — | — | EP | disclosed |
| US-9321790-B2 | Pyrimidinone derivatives as antimalarial agents | SANOFI (FR) | 2016-04-26 | — | — | US | disclosed |
| US-9321790-B2 | Pyrimidinone derivatives as antimalarial agents | SANOFI (FR) | 2016-04-26 | — | — | US | disclosed |
| US-9321790-B2 | Pyrimidinone derivatives as antimalarial agents | SANOFI (FR) | 2016-04-26 | — | — | US | disclosed |
| US-20150183804-A1 | Pyrimidinone Derivatives as Antimalarial Agents | SANOFI (FR) | 2015-07-02 | — | — | US | disclosed |
| US-20150183804-A1 | Pyrimidinone Derivatives as Antimalarial Agents | SANOFI (FR) | 2015-07-02 | — | — | US | disclosed |
| US-20150183804-A1 | Pyrimidinone Derivatives as Antimalarial Agents | SANOFI (FR) | 2015-07-02 | — | — | US | disclosed |
| EP-2870156-A1 | PYRIMIDINONE DERIVATIVES AS ANTIMALARIAL AGENTS | SANOFI (FR) | 2015-05-13 | — | — | EP | disclosed |
| US-20100081644-A1 | Compounds Which Selectively Modulate The CB2 Receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-04-01 | — | — | US | disclosed |
| WO-2010036630-A2 | COMPOUNDS WHICH SELECTIVELY MODULATE THE CB2 RECEPTOR | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-04-01 | — | — | WO | disclosed |
| WO-2010036630-A2 | COMPOUNDS WHICH SELECTIVELY MODULATE THE CB2 RECEPTOR | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-04-01 | — | — | WO | disclosed |
| US-20100081644-A1 | Compounds Which Selectively Modulate The CB2 Receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-04-01 | — | — | US | disclosed |
| US-20100081644-A1 | Compounds Which Selectively Modulate The CB2 Receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-04-01 | — | — | US | disclosed |
| EP-2142555-A1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | F. Hoffmann-Roche AG (CH) | 2010-01-13 | — | — | EP | disclosed |
| US-7625891-B2 | Heterocylic antiviral compounds | ROCHE PALO ALTO LLC (US) | 2009-12-01 | — | — | US | disclosed |
| WO-2009067613-A1 | NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS AND USES THEREOF | ABBOTT LABORATORIES (US) | 2009-05-28 | — | — | WO | disclosed |
| WO-2008119663-A1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2008-10-09 | — | — | WO | disclosed |
| US-20080249087-A1 | Heterocylic antiviral compounds | ROCHE PALO ALTO LLC | 2008-10-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100081644-A1 | Compounds Which Selectively Modulate The CB2 Receptor | CNR2, CNR1, OPRL1 | CA12 3993/4885CA1 3287/4885CA9 3589/4885 |
| US-20150183804-A1 | Pyrimidinone Derivatives as Antimalarial Agents | DHFR, PRMT1, PRMT7 | CA12 4882/4885CA1 4862/4885CA9 4874/4885 |
| US-20210130365-A1 | 2-AZASPIRO[3.4]OCTANE DERIVATIVES AS M4 AGONISTS | CHRM2, CHRM1, CHRM3 | CA12 3410/4885CA1 3339/4885CA9 3607/4885 |
| US-20080249087-A1 | Heterocylic antiviral compounds | CCR5, CCR1, CXCR1 | CA12 4710/4885CA1 4186/4885CA9 4541/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.